Dynogen Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Dynogen Pharmaceuticals Inc. is focusing on the neurological underpinnings of large, undermet GU and GI disorders including overactive bladder and irritable bowel syndrome. It is in-licensing clinical-stage compounds originally earmarked for CNS indications and developing them instead to modulate neurological targets involved in GU and GI function.
You may also be interested in...
Exploiting Connections and Navigating Bumps Along the Brain-Gut Axis
The recent setback in SUI by Lilly's depression drug duloxetine may have implcations for a handful of biotech companies aiming to exploit their knowledge of the brain-gut axis to develop CNS drugs for IBS, OAB and other below-the-belt indications. Dynogen and Vela are two companies with promising products in the area.
In Vivo's Deals Of The Month, February 2018
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)